Virpax Pharmaceuticals, Inc. (VRPX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.4300 |
| Open | 1.4500 |
| Bid | 1.3000 x 800 |
| Ask | 1.4500 x 800 |
| Day's Range | 1.3000 - 1.4700 |
| 52 Week Range | 1.1900 - 21.7900 |
| Volume | |
| Avg. Volume | 66,495 |
| Market Cap | 15.229M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7190 |
| Earnings Date | May 18, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VRPX
Related Research
- Virpax Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 08/16/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 days agoArgus Research
- Business Wire
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments
BERWYN, Pa., August 15, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the quarter ended June 30, 2022, and other recent developments.
- American City Business Journals
15 Philadelphia-area Black executives listed among the most influential in corporate America by Savoy
Fifteen of the 337 executives recognized by Savoy work in the Philadelphia region, including two sets of executives who work at the same office.
- Business Wire
Virpax Pursues OTC Medical Device Pathway for AnQlar™
BERWYN, Pa., July 05, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced it will pursue an OTC Intranasal Medical Device Consumer regulatory pathway for AnQlar™, the Company’s product candidate being developed as a prophylactic antiviral barrier against influenza and SARS-Co
